在患有晚期肺癌的患者中,使用免疫检查点抑制剂重新挑战
Li-Bo Tang1,2, Ying-Long Peng1,2, Ji Chen2
1School of Medicine, South China University of Technology, Guangzhou, China.
Nature reviews. Clinical oncology
|June 9, 2025
概括
免疫检查点抑制剂再挑战为因不良事件或进展而停止治疗的肺癌患者提供了潜在的策略. 需要进一步的研究来确定其有效性和安全性,特别是对于小细胞肺癌.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 肺癌是全球癌症死亡的主要原因,经常在晚期被诊断出来.
- 化学疗法,向疗法和免疫疗法等全身疗法是晚期肺癌的主要支柱.
- 免疫检查点抑制剂 (ICI) 是广泛使用的免疫疗法,但可能需要因免疫相关不良事件 (irAEs) 或疾病进展而停止治疗.
研究的目的:
- 为提供关于免疫检查点抑制剂 (ICI) 在肺癌中重新挑战的现有数据的全面审查.
- 检查ICI在疾病进展或免疫相关不良事件 (irAEs) 后的疗效和安全性.
- 总结当前的临床管理指南,并确定未回答的问题,用于未来的研究.
主要方法:
- 对报告肺癌患者ICI再发作的研究综合文献综述.
- 分析有关ICI在疾病进展或irrAEs后再发病的数据.
- 综合当前的临床指导和发现研究缺口.
主要成果:
- 在进展后的非小细胞肺癌或irrAEs中,ICI复发的证据有限.
- 目前对于小细胞肺癌的ICI再试剂的数据不存在.
- 该审查整合了有关安全性,疗效和临床管理策略的现有信息.
结论:
- ICI再挑战为肺癌患者提供了潜在的治疗选择,需要停止治疗.
- 在证据基础上存在显著的差距,特别是在小细胞肺癌方面.
- 进一步的研究至关重要,以确定ICI重新挑战的最佳策略,解决安全性和有效性问题.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
相关概念视频
01:27Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K